Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RNA Silencing in the Management of Dyslipidemias

1 Sept 2021

Abstract excerpt

PURPOSE OF REVIEW: Remarkable reductions in cardiovascular morbidity and mortality have been achieved in recent decades through the widespread use of 'small-molecule' hypolipidaemic drugs such as statins and ezetimibe. An alternative approach is to perturb the production of proteins through ribonucleic acid (RNA) silencing, leading to long-lasting knock-down of specific biological molecules. This review describes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV-related health complications and treatments
Share to Lipoproteins and Cardiovascular Health
Share to Microbial Metabolism and Applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34468873
DOI: 10.1007/s11883-021-00968-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNA Silencing in the Management of DyslipidemiasPMID 34468873Read ↗

Inclisiran—Silencing the Cholesterol, Speaking up the PrognosisSemantic proximity Read ↗

New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome EditingSemantic proximity Read ↗

Updates in Small Interfering RNA for the Treatment of DyslipidemiasSemantic proximity Read ↗

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseSemantic proximity Read ↗

Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL CholesterolSemantic proximity Read ↗

CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and OpportunitiesSemantic proximity Read ↗

Gene Editing for the Treatment of HypercholesterolemiaSemantic proximity Read ↗

Advances in nucleic acid-targeted therapies for cardiovascular disease preventionSemantic proximity Read ↗

Precision Regulation of LDL Metabolism: Epigenetic and Genetic Approaches Targeting LDLR, APOB, and PCSK9Semantic proximity Read ↗

Gene-based therapy in lipid management: the winding road from promise to practiceSemantic proximity Read ↗

Nucleic Acid–Based Therapies for AtherosclerosisSemantic proximity Read ↗

Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.